newsletter masthead
June 11, 2018
Midwest DNA Repair Symposium Wrap-up
Last month, the Case Comprehensive Cancer Center hosted the 20th Midwest DNA Repair Symposium, held at Thwing Center on the CWRU campus and organized by Drs. Alex Almasan, Junran Zhang and Youwei Zhang The symposium attracted 139 attendees from 10 states across the east to midwest region, as well as from Canada and China. 

Kowalczykowski - Midwest keynote The two keynote speakers,  Drs. Stephen Kowalczykowski from University of California, Davis and Lee Zou from Massachusetts General Hospital, delivered exciting research findings during this meeting .    Dr Kowalczykowski showed how BRCA1/2-Rad51 regulate DSB repair, whereas  Dr. Zou presented novel findings about A TR in regulating transcription-coupled stress. The meeting also presented a wide variety of research topics ranging basic m echanisms underlying the DNA damage response and repair, to replication checkpoints, to cell cycle control, to telomere regulation and to technologies that detect/measure DNA repair. 

Sponsors of this exciting event included BGI Inc., Tanon Inc., Cleveland Clinic, University Hospitals, Ohio State University Cancer Center, and CWRU Department of Pharmacology. 

Attendees submitted 79 abstracts for oral and poster presentations - the largest in the history of this meeting series. Ten presenters were recognized for outstanding presentations: 
DNA Repair Mtg - Poster Winners 2018

Oral Presentations
Abbey Perl - Case Western Reserve University
"A novel role for Protein Phosphatase 2A (PP2A) in the regulation of replication stress"

Tatinana Moiseeva - University of Pittsburgh
"ATR/Chk1 signaling controls replication initiation in undamaged cells"

Yaqun Teng - University of Pittsburgh
"ROS-induced RNA methylation promotes transcription-coupled homologous recombination"

Rachel Speer - University of Louisville
"Mechanisms of E2F1 suppression of RAD51 in chromate-induced failure of homologous recombination"

Poster Presentations
Brian YardCleveland Clinic
"Systematic annotation of genetic variants that determine sensitivity to radiation: a pan-cancer encyclopedia"

Lakshani PereraWayne State University
"A novel class of chemicals that react with abasic sites in DNA and specifically kill B cell cancers"

Cassandra MoyerThe Ohio State University
"Functional characterization of BRIP1 missense alleles: understanding the effects on DNA repair and cancer susceptibility"

Samantha Sanford University of Pittsburgh
"Oxidized dNTPs cause telomerase errors and chain termination"

Kayla ConnerWayne State University
"Mediation of cisplatin and carboplatin efficacy through the activation of base excision repair and mismatch repair by APOBEC3 enzymes"

Andrea ByrumWashington University in St. Louis
"TPX2/Aurora A promote replication fork stability and DNA end resection via negative regulation of 53BP1" 
Case CCC Experts Part of International "A" Team that Debuts Brain Cancer Atlas
It takes an "A" team to make headway against glioblastoma, a highly aggressive type of brain cancer. Glioblastoma is the most common type of malignant brain tumor in adults. In addition to the caliber of the researchers involved, in this case "a" also stands for atlas.

Lathia, Justin Jill Barnholtz-Sloan, PhD Key members of the team include Case CCC members  Jill S. Barnholtz-Sloan, PhD, Case CCC Associate Director for Bioinformatics and the Sally S. Morley Designated Professor in Brain Tumor Research at CWRU School of Medicine, and Justin Lathia, PhD, Assistant Professor and Associate Staff of Cellular and Molecular Medicine at the Cleveland Clinic Lerner Research Institute, who along with approximately 80 other internationally renowned neurologists, bioinformaticians, and pathologists from the United States and India recently published details of the Ivy Glioblastoma Atlas in  Science [ Puchalski, Science, 2018].

The atlas maps out comprehensive, visually-rich information on the anatomic and genetic bases of glioblastoma at the cellular and molecular levels associated with the disease. It is aimed at helping researchers and physicians improve the diagnosis and treatment of glioblastoma, including finding new drug targets. While Atlas-based data have been previously available, the new paper in  Science represents the first published research outlining the project in detail. more>
An Old Drug Learns a New Trick: Early Cancer Drug May Help Fight 'Superbugs'
Cleveland Clinic researchers have found for the first time that a drug called PALA (N-phosphonacetyl-L-aspartate) promotes the death of antibiotic-resistant bacteria in skin wounds, without the use of antibiotics. Applied as a topical lotion, the compound enhanced natural immune responses and improved the clearance of resistant bacteria in human skin.

Christine McDonald The research team, led by  Christine McDonald, PhD, Case CCC member, and Assistant Professor, Pathobiology and Associate Staff at the Cleveland Clinic Lerner Research Institute, previously discovered that a protein called NOD2 activates antimicrobial peptides-tiny proteins that are part of the body's arsenal of natural defenses against pathogens. They hypothesized that turning up the activity of NOD2 might facilitate pathogen defense, particularly in the skin, which is the body's primary barrier against infection.

While NOD2 is an attractive target, it acts mainly as a facilitator of immune responses, rather than having a distinct physiological activity of its own. This has made it difficult for researchers to modify its actions in the laboratory. In the new study,  published in Scientific Reports [Jatana, Sci Reports, 2018], Dr. McDonald and her team discovered for the first time that NOD2 activity in the skin is controlled by an enzyme that does in fact have a targetable activity-a protein called CAD. more>
Lymphoma and Leukemia Drug May Also Treat Deadly Brain Cancer
New Cleveland Clinic research suggests that Ibrutinib, a drug recently approved by the FDA to treat lymphoma and leukemia, may also help treat glioblastoma (GBM)-the most common and lethal type of brain cancer. The promising study findings,  published in Science Translational Medicine [Shi, Sci Transl Med, 2018], offer hope that Ibrutinib may one day help improve GBM patient outcomes and survival, which currently are exceptionally poor.

Shideng Bao The team of researchers, led by  Shideng Bao, PhD, Case CCC member, and Assistant Professor and Associate Staff in the Cleveland Clinic  Lerner Research Institute Department of Stem Cell Biology & Regenerative Medicine, found that Ibrutinib suppressed tumor growth and increased survival in a preclinical model of GBM. Ibrutinib was significantly more effective in slowing tumor growth than the current standard-of-care GBM chemotherapy drug, Temozolomide, and extended average survival rate by more than 10-fold. more>
Join Team Case CCC!
VeloSano logo
Register today for  VeloSano Bike to Cure , 20-22, 2018!  

It's hard to believe there is less than 2 months left before VeloSano weekend!  Team Case CCC is going strong so far, and continuing to recruit at Case CCC institutions. 

Remember - to be eligible for Case CCC VeloSano pilot funding you must participate in VeloSano as a rider or volunteer and be a Case CCC member. 

We are one of the top teams - join us and help to raise money to fund cancer research in Cleveland! 
VeloSano Pilot Awardees 2018
VeloSano logo
Congratulations to the most recent group of pilot awardees supported by VeloSano Bike to Cure. All lead PIs or their lab members 

Awards were made as part of a competitive RFA process to multi-investigator teams/projects that align with one of the six Case CCC research initiatives. PIs or their lab members must have participated in the VeloSano Bike to Cure event as a rider, virtual rider, or volunteer.

Alex Huang Alex Huang, MD, PhD
"Novel molecular signatures in Shh medulloblastoma defines immune phenotypes and predicts immunotherapeutic response"

Mark Jackson, PhD
Mark Jackson, PhD
"Combating resistance to immune checkpoint inhibition; identifying   new targets using in vivo forward   genetics screening"

Ruth Keri, PhD
"The oncogenic impact of LIN9 in  triple negative breast cancer"

Richard Lee Richard Lee, MD
"Identifying the molecular targets of mistletoe lectin I for drug development in hepatocellular carcinoma"

Reshmi Parameswaran Reshmi Parameswaran, PhD, MS
"Targeting hexosamine biosynthetic pathway for acute myeloid leukemia therapy"

Horst von Recum Horst von Recum, PhD
"A refillable drug delivery device
of treating recurrent brain

David Wald, MD, PhD
"Targeting thioredoxin reductase in AML"
Annual Scientific Retreat 2018
Jul 26-27, 2018
The Retreat Organizing Committee is excited to announce that  registration is open for the Case CCC scientific retreat, July 26-27, 2018.

The keynote address will be Hsing-Jien Kung delivered Thursday, July 26 at the Tinkham Veale University Center by Dr. Hsing-Jien Kung, Deputy Director and and Director of Basic Research and Distinguished Professor, Dept. Biochemistry and Molecular Medicine, UC Davis at University of California, Davis.  Thursday's program will also feature an update from Cancer Center Director Dr. Stan Gersona judged student/trainee poster session, and a reception. 

Friday's program will be held at Corporate College East. The agenda will focus on the scientific initiatives and really get into the research being conducted by our Center. Leaders of the scientific initiatives will provide a brief overview, then we will hear scientific presentations being conducted within those initiatives, plus presentations to highlight exciting services and technology provided by Cancer Center shared resources. 

Stay tuned for more details. 

Organizing Committee: 
John Wang, PhD, (Chair); Stan Gerson, MD; Magdalena Grabowska, PhD; Christopher Hoimes, OD; Damian Junk, PhD; Ruth Keri, PhD; Byron Lee, MD, PhD; Aziz Nazha, MD; Agne Petrosuite, MD; Johnie Rose, MD, PhD; Fred Schumacher, PhD, MPH; Martina Veigl, PhD; Jennifer Yu, MD, PhD; Vinay Varadan, PhD

CSC 2018 - web banner

Cancer Stem Cell Conference
Aug 6-8, 2018 | Tinkham Veale 

The Case Comprehensive Cancer Center (Case CCC) and National Center for Regenerative Medicine (NCRM) invite you to Cancer Stem Cell Conference (CSC 2018)! Now in it's third year, CSC 2018 will feature renowned thought leaders in the field of cancer stem cell research. This conference is guaranteed to offer cutting-edge keynote presentations from a variety of niches within the field. Join world-class investigators for this 3-day summit and network with scientists and clinicians advancing cancer stem cell research and therapeutic applications.

Conference Highlights
  • The agenda will integrate invited talks from thought leaders in the CSC field with short talks from early-stage investigators and trainees selected from submitted abstracts.
  • Pre-conference career development workshop for junior faculty and trainees
    • Meet the Editors: Natalie Cain, PhD (CellReports), Mark Landis, PhD (CancerDiscovery) and Teodoro Pulvirenti, PhD (JEM)
    • Discussion of NIH grants: Michael Espey, PhD (NCI) and Michelle McGuirl, PhD (NIH)
  • Young Investigator Awards available to support travel for senior trainees or junior faculty (less than 5 years from their first independent position). 
  • Opportunity to share ideas with world-class investigators in stem cell research. 2016 CSC was attended by over 300 from 20 countries and 25 U.S. states. This year's conference is on track to attract a similar crowd of colleagues.
Keynote Speakers
  • Norman E. 'Ned' Sharpless, MD (NCI)
  • John S. Condeelis, PhD (Einstein)
  • Irving Weissman, MD (Stanford)
  • Zena Werb, PhD (UCSF)
Medcity News - Jun 6, 2018
Recent research on brain metastasis from two disparate primary malignancies (non-small cell lung cancer and gastroesophageal cancer) may impact patient care in each case. Abstracts presented by Cleveland Clinic researchers at the 2016  American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this weekend communicated related findings.
"Brain metastases is a significant and serious complication of systemic cancers - 10 times more common than primary malignant brain tumors, so this is an important clinical problem we see in clinic every day," said  Dr. Manmeet Ahluwalia, Case Comprehensive Cancer Center, director of Cleveland Clinic's Brain Metastasis Research Program and a study author.
Microsoft, Case Western Reserve University partner on magnetic fingerprinting - May 18, 2018
Case Western Reserve University and Microsoft are partnering to advance how doctors can use non-invasive scans to detect disease.  Researchers at CWRU published research in 2013 on "magnetic resonance fingerprinting." Despite the name, this doesn't mean that technicians would get medical information from your fingerprint... "Quantum computing provides an opportunity to find the truly best way to scan patients," CWRU radiology professor Mark Griswold said in a press release. "We are so excited to explore how far we can push these new quantum and quantum-inspired methods beyond traditional computer algorithms."
Opportunities for Pilot Projects in Cancer Disparities Research
Deadline: Jul 2, 2018
The Office of Cancer Disparities Research of the Case Comprehensive Cancer Center is providing seed funding for highly innovative and impactful disparities-focused proposals that will generate key data for larger, nationally competitive grants. Attention to cancer disparities (or catchment area) is a cross-cutting theme across the scientific programs; thus projects aligned with the Center's strategic plan, and specifically the Community and Cancer Health Disparities scientific initiative, are preferred. Collaborative, multi-investigator projects are particularly encouraged. The main goal of this RFA is to stimulate novel research designed to (1) improve understanding of factors that contribute to cancer disparities and (2) develop and test interventions for reducing and ultimately eliminating them. Transdisciplinary, interprogrammatic, and translational approaches are especially encouraged, as are new investigator proposals.
NIH BULLETIN- Notices and Funding Opportunities
Request for Information on the Development of the FY 2021-2023 Trans-NIH Plan for HIV-Related Research (NOT-OD-18-185)

Notice of Availability of Administrative Supplements to Support Acquisition and Annotation of Biospecimens from Racial/Ethnically Diverse Cancer Patients for the Development of Models for the Human Cancer Models Initiative (HCMI)(NOT-CA-18-076)

Notice of NIBIB Participation in PAR-18-331"Simulation Modeling and Systems Science to Address Health Disparities (R01 Clinical Trial Not Allowed)"(NOT-EB-18-016)

Notice of Availability of Administrative Supplements to NIBIB C3i Participants for Advancing Innovation (NOT-EB-18-018)

Program Announcements

Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) (RFA-TR-18-020)
Deadline: Oct 9, 2018

Administrative Supplements for Research on Dietary Supplements (Admin Supp - Clinical Trial Not Allowed)(PA-18-817)
Deadline: Oct 15, 2018; Jan 15, 2019; Apr 15, 2019; Oct 15, 2019; Jan 15, 2020; or Apr 15, 2020

Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp -  Clinical Trial Not Allowed)(PA-18-818)
Deadline: Oct 15 2018, Jan 15 2019, Apr 15 2019, Oct 15 2019, Jan 15 2020, and Apr 15 2020

Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed)(PA-18-821) 
Deadline: Jul 30, 2018
Tues, Jun 12
Radiation Oncology Grand Rounds
Chad Zender, MD
Associate Professor, Otolaryngology,  CWRU/UHCMC
"Partial laryngectomy indications and outcomes"
8:10a Lerner B-151

Cancer Impact Lecture
Lily Wang, PhD
Medical College of Wisconsin
"Chalk Talk"
1p NE1-205 

Cancer Biology Seminar
Arishya Sharma, PhD Research Fellow, Almasan Lab, Cancer Biology, Cleveland Clinic "Autophagy and USP14 role in non-homologous end joining"
2p NC1-202
Wed, Jun 13
PRCHN Seminar
Scott Frank, MD, MS Professor, CWRU "Precision Public Health: Using health information technology to improve our approach to community building"
12p PRCHN conf rm
Thurs, Jun 14
Developmental Therapeutics Journal Club
9a R4-013
Fri, Jun 15
TCI Grand Rounds
8a Ca5-120
Mon, Jun 18
Cancer Center Research Chalk Talk
1p WRB 3-136
Thurs, Jun 21
Developmental Therapeutics Journal Club
9a R4-013
Fri, Jun 22
TCI Grand Rounds
8a Ca5-120


Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center 
2103 Cornell Road, Ste 1422
Cleveland, OH 44106-7285